Therefore, we speculate that on the one hand tofacitinib-induced differentiation towards classical TH17 cells is followed by a reduction of IFN-γ secretion that is beneficial for patients with autoimmune diseases but on the other hand it facilitates VZV reactivation. This evidence concerns the gene IFNG and autoimmune disease.